【摘要】 目的 观察Basiliximab(舒莱)在致敏或二次肾移植受者中应用的有效性和安全性。方法 61例致敏及二次移植受者，随机分为舒莱组24例，对照组37例。所有患者均接受普乐可复/环孢素A+骁悉+强的松三联疗法。舒莱组分别在术前2h和术后第4天静脉内输入20mg舒莱。观察两组术后3月内急性排斥(AR)、移植肾功能延迟恢复(DGF)、6个月内并发症发生及人/肾存活情况。结果 3个月内舒莱组和对照组分别有2例(8.3%)和14例(37.8%)发生AR(P<0.05)。术后DGF的发生率、术后6个月内并发症及人/肾存活率在两组间差异无显著性。结论 舒莱是一种强效、安全的预防急性排斥的免疫抑制剂，在致敏及二次移植受者的免疫治疗中效果满意。

    Lin Minzhuan，Ming Aimin，Zhao Ming.

    Department of Organ Transplantation，China Southern Center of Biological Diagnosis&Therapy，Guangzhou510730.

    【Abstract】 Objective To explore the efficacy and safety of basiliximab(Simulect)induction therapy in senˉsitized and second-operation recipients following renal transplantation.Methods 61sensitized recipients were retroˉspectively analyzed and divided into treatment group(n=24)and control group(n=37).Main immunosuppressive therapy regimen consisted of tacrolimus or cyclosporine，mycophenolate mofetil and steroids ......